Shankar-Hari, M; Saha, R; Wilson, J; Prescott, HC; Harrison, D; Rowan, K; Rubenfeld, GD; Adhikari, NKJ in [Shankar-Hari, Manu; Wilson, Julie] St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, ICU Support Off, 1st Floor,East Wing, London SE1 7EH, England; [Shankar-Hari, Manu; Saha, Rohit] Kings Coll London, Sch Immunol & Microbial Sci, London SE1 9RT, England; [Shankar-Hari, Manu; Harrison, David; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, Napier House,24 High Holborn, London WC1V 6AZ, England; [Prescott, Hallie C.] Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Prescott, Hallie C.] Univ Michigan Hlth Syst, VA Ctr Clin Management Res, Ann Arbor, MI USA; [Rubenfeld, Gordon D.; Adhikari, Neill K. J.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON M4N 3M5, Canada; [Rubenfeld, Gordon D.; Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, 2075 Bayview Ave,D1-08, Toronto, ON M4N 3M5, Canada published Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis in 2020, Cited 86. Recommanded Product: 83-10-3. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.
Purpose Sepsis survivors have a higher risk of rehospitalisation and of long-term mortality. We assessed the rate, diagnosis, and independent predictors for rehospitalisation in adult sepsis survivors. Methods We searched for non-randomized studies and randomized clinical trials in MEDLINE, Cochrane Library, Web of Science, and EMBASE (OVID interface, 1992-October 2019). The search strategy used controlled vocabulary terms and text words for sepsis and hospital readmission, limited to humans, and English language. Two authors independently selected studies and extracted data using predefined criteria and data extraction forms. Results The literature search identified 12,544 records. Among 56 studies (36 full and 20 conference abstracts) that met our inclusion criteria, all were non-randomised studies. Studies most often report 30-day rehospitalisation rate (mean 21.4%, 95% confidence interval [CI] 17.6-25.4%; N = 36 studies reporting 6,729,617 patients). The mean (95%CI) rehospitalisation rates increased from 9.3% (8.3-10.3%) by 7 days to 39.0% (22.0-59.4%) by 365 days. Infection was the most common rehospitalisation diagnosis. Risk factors that increased the rehospitalisation risk in sepsis survivors were generic characteristics such as older age, male, comorbidities, non-elective admissions, hospitalisation prior to index sepsis admission, and sepsis characteristics such as infection and illness severity, with hospital characteristics showing inconsistent associations. The overall certainty of evidence was moderate for rehospitalisation rates and low for risk factors. Conclusions Rehospitalisation events are common in sepsis survivors, with one in five rehospitalisation events occurring within 30 days of hospital discharge following an index sepsis admission. The generic and sepsis-specific characteristics at index sepsis admission are commonly reported risk factors for rehospitalisation. Registration PROSPERO CRD 42016039257, registered on 14-06-2016.
About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Shankar-Hari, M; Saha, R; Wilson, J; Prescott, HC; Harrison, D; Rowan, K; Rubenfeld, GD; Adhikari, NKJ or concate me.. Recommanded Product: 83-10-3
Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics